Antiarthritis effect of a novel Bruton's Tyrosine Kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/ pharmacodynamic modeling: Relationships between inhibition of BTK phosphorylation and efficacy

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 154-163

  Liu, Lichuan ^a   Di Paolo, Julie ^b,c   Barbosa, Jim ^b,c   Rong, Hong ^b,c   Reif, Karin ^a   Wong, Harvey ^a  

^a GENENTECH INC   (United States)

^b CGI Pharmaceuticals Inc   (United States)

^c Gilead Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BRUTON TYROSINE KINASE; GDC 0834; N [3 [6 [4 (1,4 DIMETHYL 3 OXOPIPERAZIN 2 YL)PHENYLAMINO] 4 METHYL 5 OXO 4,5 DIHYDROPYRAZIN 2 YL] 2 METHYLPHENYL] 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE 2 CARBOXAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE EDEMA; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CATTLE; FEMALE; MALE; MICE; MICE, INBRED BALB C; MODELS, CHEMICAL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINONES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; THIOPHENES; TREATMENT OUTCOME;

EID: 79959522607     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181545     Document Type: Article

References (30)

1. Bendele A (2001) Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact 1:377-385.
2. Brunner C, Müller B, and Wirth T (2005) Bruton's tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol 20:945-955. (Pubitemid 40932612)
3. Burnette WN (1981) "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112:195-203.
4. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, et al. (2011) Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7:41-50.
5. Earp JC, Dubois DC, Almon RR, and Jusko WJ (2009) Quantitative dynamic models of arthritis progression in the rat. Pharm Res 26:196-203.
6. Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Almon RR, and Jusko WJ (2008a) Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther 326:546-554.
7. Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, and Jusko WJ (2008b) Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther 326:532-545.
8. Eisenberg R and Albert D (2006) B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2:20-27. (Pubitemid 43153645)
9. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed. Marcel Dekker, New York.
10. Hegen M, Keith JC Jr., Collins M, and Nickerson-Nutter CL (2008) Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 67:1505-1515.
11. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075-13080.
12. Khan WN, Alt FW, Gerstein RM, Malynn BA, Larsson I, Rathbun G, Davidson L, Müller S, Kantor AB, and Herzenberg LA (1995) Defective B cell development and function in Btk-deficient mice. Immunity 3:283-299.
13. Lebakken CS, Riddle SM, Singh U, Frazee WJ, Eliason HC, Gao Y, Reichling LJ, Marks BD, and Vogel KW (2009) Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. J Biomol Screen 14:924-935.
14. Mager DE, Woo S, and Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16-24.
15. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518. (Pubitemid 36444157)
16. Marinova-Mutafchieva L, Gabay C, Funa K, and Williams RO (2006) Remission of collagen-induced arthritis is associated with high levels of transforming growth factor-β expression in the joint. Clin Exp Immunol 146:287-293. (Pubitemid 44581344)
17. Mease PJ (2008) B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 35:1245-1255.
18. Niiro H and Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2:945-956. (Pubitemid 37323215)
19. Pan Z (2008) Bruton's tyrosine kinase as a drug discovery target. Drug News Perspect 21:357-362.
20. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, et al. (2007) Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2:58-61.
21. Satterthwaite AB and Witte ON (2000) The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 175:120-127. (Pubitemid 30427162)
22. Scott DL, Wolfe F, and Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094-1108.
23. Sharma S, Orlowski G, and Song W (2009) Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J Immunol 182:329-339.
24. Smolen JS and Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473-488. (Pubitemid 37361728)
25. Townsend MJ, Monroe JG, and Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 237:264-283.
26. Trentham DE, Townes AS, and Kang AH (1977) Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 146:857-868. (Pubitemid 8175993)
27. Van Doornum S, Jennings GL, and Wicks IP (2006) Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 184:287-290.
28. Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, and Choo EF (2009) Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5- yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther 329:360-367.
29. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, and Koudriakova T (2008) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267-1274. (Pubitemid 351929310)
30. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, and Tedder TF (2008) B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223:284-299. (Pubitemid 351986191)